Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Commentary
  • Published:

As we bring demethylating drugs to the clinic, we better know the DICE being cast

Oncogene volume 29, pages 5772–5774 (2010)Cite this article

Subjects

Abstract

In this issue, Weber and coworkers report that DNA-demethylating drugs alter the transcriptional expression of the cMet proto-oncogene. Abnormal transcription is driven by the antisense promoter of a Line-1 repetitive element present within an intron. The element is a recent addition to the genome and is absent in animal models of cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  • Apostolou E, Thanos D . (2008). Virus infection induces NF-κB-dependent interchromosomal associations mediating monoallelic IFN-beta gene expression. Cell 134: 85–96.

    Article  CAS  Google Scholar 

  • Comfort NC . (2001). From controlling elements to transposons: Barbara McClintock and the Nobel Prize. Endeavour 25: 127–130.

    Article  CAS  Google Scholar 

  • Faulkner GJ, Kimura Y, Daub CO, Wani S, Plessy C, Irvine KM et al. (2009). The regulated retrotransposon transcriptome of mammalian cells. Nat Genet 41: 563–571.

    Article  CAS  Google Scholar 

  • Lamprecht B, Walter K, Kreher S, Kumar R, Hummel M, Lenze D et al. (2010). Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma. Nat Med 16: 571–579.

    Article  CAS  Google Scholar 

  • Penzkofer T, Dandekar T, Zemojtel T . (2005). L1Base: from functional annotation to prediction of active LINE-1 elements. Nucleic Acids Res 33 (Database issue): D498–D500.

    Article  CAS  Google Scholar 

  • Rangwala SH, Zhang L, Kazazian Jr HH . (2009). Many LINE1 elements contribute to the transcriptome of human somatic cells. Genome Biol 10: R100.

    Article  Google Scholar 

  • Roman-Gomez J, Jimenez-Velasco A, Agirre X, Cervantes F, Sanchez J, Garate L et al. (2005). Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia. Oncogene 24: 7213–7223.

    Article  CAS  Google Scholar 

  • Saito Y, Suzuki H, Tsugawa H, Nakagawa I, Matsuzaki J, Kanai Y et al. (2009). Chromatin remodeling at Alu repeats by epigenetic treatment activates silenced microRNA-512-5p with downregulation of Mcl-1 in human gastric cancer cells. Oncogene 28: 2738–2744.

    Article  CAS  Google Scholar 

  • Speek M . (2001). Antisense promoter of human L1 retrotransposon drives transcription of adjacent cellular genes. Mol Cell Biol 21: 1973–1985.

    Article  CAS  Google Scholar 

  • Szpakowski S, Sun X, Lage JM, Dyer A, Rubinstein J, Kowalski D et al. (2009). Loss of epigenetic silencing in tumors preferentially affects primate-specific retroelements. Gene 448: 151–167.

    Article  CAS  Google Scholar 

  • Weber B, Kimhi S, Howared G, Eden A, Lyko F . (2010). Demethylation of a LINE-1 antisense promoter in the cMet locus impairs Met signaling through induction of illegitimate transcription. Oncogene 29: 5775–5784.

    Article  CAS  Google Scholar 

  • Wolff EM, Byun HM, Han HF, Sharma S, Nichols PW, Siegmund KD et al. (2010). Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer. PLoS Genet 6: e1000917.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Interdepartmental Computational Biology & Bioinformatics Program, Yale University School of Medicine, New Haven, CT, USA

    P M Lizardi

Authors
  1. P M Lizardi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P M Lizardi.

Ethics declarations

Competing interests

The author declares no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lizardi, P. As we bring demethylating drugs to the clinic, we better know the DICE being cast. Oncogene 29, 5772–5774 (2010). https://doi.org/10.1038/onc.2010.372

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2010.372

This article is cited by

Search

Advanced search

Quick links